tirzepatide by eli lilly Patients Taking Experimental Obesity Drug Lost More Than 50 Pounds, Maker Claims Eli Lilly says weight loss

Common violations include CPOM breaches, improper delegation, unlicensed practice, false advertising, inadequate prescribing documentation, and telehealth consent failures

This is another reason why the medication and breastfeeding are considered incompatible

Cover Image Illustration by: The Optimal Medical Group

Medical weight management is a clinician-guided approach to weight loss that may include FDA-approved medications, nutrition guidance, and lifestyle support to help patients achieve sustainable results

Retatrutide is a novel, investigational injectable medication designed for weight reduction and metabolic optimization

doi: 10.1016/j.xcrm.2025.102156